Investors in Tenax Therapeutics have until December 28, 2026, to seek lead plaintiff status in a securities lawsuit alleging the company misrepresented the potential of its TNX-103 drug candidate across three separate financing rounds.
The securities lawsuit stems from the Phase 3 LEVEL trial of TNX-103 missing its primary endpoint, with the company allegedly building confidence across three financings over a 33-month period. A lead plaintiff deadline of December 28, 2026 keeps litigation overhang in focus. The trial failure itself was likely disclosed earlier, but the ongoing lawsuit and deadline reminder reinforce negative sentiment for holders.
The lawsuit alleges the company built confidence in TNX-103 across three financings before its Phase 3 LEVEL trial missed its primary endpoint.
The deadline is December 28, 2026.
Tenax Therapeutics, Inc. is under legal scrutiny as Levi & Korsinsky, LLP reminds investors of a December 28, 2026, lead plaintiff deadline. The class action lawsuit centers on allegations that the company misled shareholders regarding the efficacy of TNX-103 prior to its Phase 3 LEVEL trial failing to meet its primary endpoint.
The lawsuit alleges that Tenax Therapeutics misled investors by building confidence in its TNX-103 drug candidate across three financing rounds before the Phase 3 LEVEL trial failed to meet its primary endpoint.
Investors who purchased Tenax Therapeutics securities have until December 28, 2026, to apply to be a lead plaintiff in the class action lawsuit.